The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure trial (DAPA-HF) is an international, multi-center, randomized double-blinded controlled trial to determine the safety and efficacy of SGLT-2 inhibitor dapagliflozin added to the conventional heart failure therapy in patients with heart failure with reduced ejection fraction [25]. Here, SLC5A2 is linked to hydrops fetalis.